Celcuity Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Celcuity wird ein Gewinn- und Umsatzwachstum von 27.6% bzw. 73.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 32.9% pro Jahr wachsen soll.

Wichtige Informationen

27.6%

Wachstumsrate der Gewinne

32.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	73.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Celcuity rises after hours on FDA Breakthrough Therapy nod for its breast cancer treatment

Jul 18

Is Celcuity (NASDAQ:CELC) A Risky Investment?

Jan 27

Health Check: How Prudently Does Celcuity (NASDAQ:CELC) Use Debt?

Sep 21

Celcuity: Nipping The Oncogenic Bud

Jul 08

What You Need To Know About Celcuity Inc.'s (NASDAQ:CELC) Investor Composition

Mar 14

We're Hopeful That Celcuity (NASDAQ:CELC) Will Use Its Cash Wisely

Jan 20

Celcuity inks clinical trial pact with Massachusetts General Hospital and Puma Technologies

Dec 23

Could The Celcuity Inc. (NASDAQ:CELC) Ownership Structure Tell Us Something Useful?

Nov 29

Celcuity EPS beats by $0.03

Nov 09

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CELC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	50	-159	-88	-159	6
12/31/2025	1	-144	-94	-131	7
12/31/2024	N/A	-105	-70	-77	7
9/30/2024	N/A	-94	-74	-74	N/A
6/30/2024	N/A	-83	-67	-66	N/A
3/31/2024	N/A	-73	-58	-58	N/A
12/31/2023	N/A	-64	-54	-54	N/A
9/30/2023	N/A	-57	-45	-45	N/A
6/30/2023	N/A	-49	-41	-41	N/A
3/31/2023	N/A	-45	-43	-43	N/A
12/31/2022	N/A	-41	-36	-36	N/A
9/30/2022	N/A	-36	-33	-33	N/A
6/30/2022	N/A	-31	-27	-27	N/A
3/31/2022	N/A	-35	-24	-24	N/A
12/31/2021	N/A	-30	-20	-20	N/A
9/30/2021	N/A	-25	-16	-16	N/A
6/30/2021	N/A	-22	-14	-14	N/A
3/31/2021	N/A	-10	-8	-8	N/A
12/31/2020	N/A	-9	-7	-7	N/A
9/30/2020	N/A	-9	-7	-7	N/A
6/30/2020	N/A	-8	-7	-7	N/A
3/31/2020	N/A	-8	-7	-6	N/A
12/31/2019	N/A	-7	-6	-6	N/A
9/30/2019	N/A	-7	-6	-6	N/A
6/30/2019	N/A	-7	-7	-6	N/A
3/31/2019	N/A	-7	-7	-6	N/A
12/31/2018	N/A	-7	-7	-6	N/A
9/30/2018	N/A	-7	-6	-6	N/A
6/30/2018	N/A	-7	N/A	-6	N/A
3/31/2018	N/A	-7	N/A	-5	N/A
12/31/2017	N/A	-6	N/A	-5	N/A
9/30/2017	N/A	-5	N/A	-5	N/A
6/30/2017	N/A	-5	N/A	-4	N/A
3/31/2017	N/A	-4	N/A	-3	N/A
12/31/2016	N/A	-3	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CELC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CELC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CELC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CELCDie Einnahmen des Unternehmens (73.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: CELCDie Einnahmen des Unternehmens (73.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CELC in 3 Jahren voraussichtlich hoch sein wird

Celcuity Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.7% to US$29.50

Price target increased by 11% to US$27.40

Price target decreased to US$24.00

Price target decreased to US$30.50

Recent updates

Celcuity Inc. to Report Q3, 2024 Results on Nov 14, 2024

Celcuity: Breast Cancer Drug Developer With Upcoming Catalysts

Is Celcuity (NASDAQ:CELC) Using Too Much Debt?

Celcuity Inc. to Report Q2, 2024 Results on Aug 14, 2024

Celcuity: Flying A Phase 3 Trial Right Under Your Nose

Celcuity Inc. has completed a Follow-on Equity Offering in the amount of $60.0005 million.

New major risk - Shareholder dilution

Celcuity Inc. Announces Plan to Initiate A Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Celcuity Inc. to Report Q1, 2024 Results on May 15, 2024

Does Celcuity (NASDAQ:CELC) Have A Healthy Balance Sheet?

Price target increased by 7.7% to US$29.50

Celcuity Inc., Annual General Meeting, May 09, 2024

Celcuity Inc. to Report Q4, 2023 Results on Mar 27, 2024

Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer

Price target increased by 11% to US$27.40

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

Celcuity Inc. Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

New major risk - Revenue and earnings growth

Celcuity Inc. to Report Q3, 2023 Results on Nov 13, 2023

Celcuity Inc. announced that it expects to receive $50 million in funding

Celcuity Inc. Announces Plan to Conduct Phase 1B/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

New major risk - Revenue and earnings growth

Celcuity Inc. to Report Q2, 2023 Results on Aug 10, 2023

Is Celcuity (NASDAQ:CELC) Using Too Much Debt?

Independent Director recently bought US$103k worth of stock

Celcuity Inc. to Report Q1, 2023 Results on May 15, 2023

Celcuity Inc. Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer

Celcuity to Present Additional Data for Gedatolisib At the 2022 San Antonio Breast Cancer Symposium

Price target decreased to US$24.00

Insufficient new directors

Celcuity Inc. Appoints Polly A. Murphy to its Audit Committee and Its Compensation Committee

Celcuity Inc. to Report Q3, 2022 Results on Nov 10, 2022

Celcuity Inc. Appoints Polly Murphy to Board of Directors

Is Celcuity (NASDAQ:CELC) A Risky Investment?

Celcuity Inc. to Report Q2, 2022 Results on Aug 11, 2022

Celcuity rises after hours on FDA Breakthrough Therapy nod for its breast cancer treatment

Insufficient new directors

Price target decreased to US$30.50

Celcuity Inc. to Report Q1, 2022 Results on May 16, 2022

Celcuity Inc., Annual General Meeting, May 12, 2022

Is Celcuity (NASDAQ:CELC) A Risky Investment?

Health Check: How Prudently Does Celcuity (NASDAQ:CELC) Use Debt?

Celcuity: Nipping The Oncogenic Bud

Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen

What You Need To Know About Celcuity Inc.'s (NASDAQ:CELC) Investor Composition

New 90-day high: US$17.80

New 90-day high: US$14.95

Celcuity Inc. Announces Breast Cancer Clinical Trial Collaboration with Sarah Cannon and Pfizer to Study New Drug Regimen

We're Hopeful That Celcuity (NASDAQ:CELC) Will Use Its Cash Wisely

New 90-day high: US$11.97

Celcuity inks clinical trial pact with Massachusetts General Hospital and Puma Technologies

Could The Celcuity Inc. (NASDAQ:CELC) Ownership Structure Tell Us Something Useful?

New 90-day high: US$6.55

Celcuity EPS beats by $0.03

Celcuity Inc. to Report Q2, 2020 Results on Aug 10, 2020

Celcuity Inc.(NasdaqCM:CELC) dropped from Russell 2000 Dynamic Index

Celcuity Inc.(NasdaqCM:CELC) dropped from Russell Small Cap Completeness Index

Celcuity Inc.(NasdaqCM:CELC) dropped from Russell 3000 Growth Index

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken